
|Articles|September 1, 2003
Patient compliance improves with twice-daily dosing
Fort Lauderdale, FL-A twice-daily dosing regimen of pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., of Napa, CA, and Tampere, Finland) is as effective as the four-times-daily regimen of the drug for treating seasonal allergic conjunctivitis. The simpler dosing regimen may enhance patient compliance.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
2
Evolving glaucoma therapy: A new era of interventional strategies
3
Throwback Series: Managing bilateral diabetic macular edema early in practice
4
ICYMI: AAO 2025 showcases new technologies and continued research
5

















































.png)


